<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658537</url>
  </required_header>
  <id_info>
    <org_study_id>ASPIRE-single</org_study_id>
    <nct_id>NCT04658537</nct_id>
  </id_info>
  <brief_title>Advanced Techniques for Single-fraction Palliative Radiotherapy Versus ASPIRE-single</brief_title>
  <acronym>ASPIRE single</acronym>
  <official_title>Advanced Techniques for Single-fraction Palliative Radiotherapy Versus Standard Single Fraction Radiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal North Shore Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal North Shore Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      One third of patients treated in the radiation oncology departments are treated with&#xD;
      palliative intent. These patients can be unwell due to their advanced disease and suffering&#xD;
      from pain and other symptoms related to metastases. Radiation therapy (RT) has an important&#xD;
      role in the symptomatic relief and improvement in the quality of life (QoL) for these&#xD;
      patients.The aim of the study is to determine if escalated single fraction palliative&#xD;
      radiotherapy using intensity-modulated techniques results in a prolonged duration of benefit&#xD;
      for patients otherwise suitable for standard single fraction radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiation therapy (RT) has an important role in the symptomatic relief and improvement in the&#xD;
      quality of life (QoL) for palliative patients who can be unwell due to their advanced disease&#xD;
      and who suffer from pain and other symptoms related to metastases.&#xD;
&#xD;
      A single fraction of 8Gy is considered a standard treatment. In an assessment of health&#xD;
      related quality of life (HRQoL) after palliative RT for painful bone metastases, the overall&#xD;
      radiotherapy response at 1 week was 45% and by week 2 was 62%. Patients had a significant&#xD;
      decrease in pain, insomnia and constipation by 1 month post treatment and an improvement in&#xD;
      emotional functioning. When RT is used to control a bleeding tumour, up to 90% of patients&#xD;
      will experience haemostasis.&#xD;
&#xD;
      There is however concern that 8 Gy in 1 fraction will not provide a durable response, with up&#xD;
      to 20% of patients requiring retreatment to the same site, compared with 8% who receive&#xD;
      multiple fraction treatment. Single fraction palliative radiation therapy (SFRT) is therefore&#xD;
      an under utilised treatment regimen.&#xD;
&#xD;
      To implement the higher doses with a single fraction, more advanced radiation techniques are&#xD;
      required, and there is still equipoise regarding the benefits. With advances in linear&#xD;
      accelerator design and software, it is now possible to treat patients with advanced radiation&#xD;
      techniques and low resources. Standard clinical pathways including computer optimised&#xD;
      planning, remote (virtual) QA of plan delivery and the use of diagnostic imaging for planning&#xD;
      are all feasible (under currently in clinical use at Northern Sydney Cancer Centre).&#xD;
&#xD;
      The results from this study will be used to design / proceed to a Randomised Phase III study,&#xD;
      if appropriate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2021</start_date>
  <completion_date type="Anticipated">May 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 29, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Non Comparative Randomised Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Treatment arm will be masked to investigators. Participants will not be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Substantial benefit from palliative radiotherapy</measure>
    <time_frame>9 months</time_frame>
    <description>to determine the percentage of patients who achieved a substantial benefit from palliative radiotherapy and have not redeveloped symptoms by 9 months post treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Wait Time</measure>
    <time_frame>1 week</time_frame>
    <description>The time from the date of the initial consultation and radiation therapy consent to the start date of radiation therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation Department Time</measure>
    <time_frame>1 day</time_frame>
    <description>The time in the radiation oncology department for radiation therapy, from arrival time in the department until the patient is ready for collection at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy Treatment Time</measure>
    <time_frame>1 day</time_frame>
    <description>The time that the patient is in the Radiation therapy treatment room, from time of entry to time of exit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion Rates of ePRO's in a Palliative Care Cohort</measure>
    <time_frame>2 years</time_frame>
    <description>The rate at which baseline and post treatment questionnaires are completed by both patients and primary carers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing Patient and Carer Assessments</measure>
    <time_frame>2 years</time_frame>
    <description>Comparing the answers given by patients and carers to determine whether carers can accurately answer on behalf of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation Doses to Organs at Risk</measure>
    <time_frame>2 years</time_frame>
    <description>The radiation doses delivered to the surrounding organs at risk will be reviewed during and after treatment completion to ensure that they meet predefined OAR constraints Patient and carer reported toxicity from treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>24 months</time_frame>
    <description>Electronic questionnaires delivered to the patient pre-treatment and post treatment at 1, 3, 6, 9, 12, 18, and 24 months. Scores will be calculated in accordance with established scoring methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carer Reported Outcomes</measure>
    <time_frame>24 months</time_frame>
    <description>Electronic questionnaires delivered to the patient's primary carer pre-treatment and post treatment at 1, 3, 6, 9, 12, 18, and 24 months. Scores will be calculated in accordance with established scoring methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of treatment</measure>
    <time_frame>2 years</time_frame>
    <description>this will be determined by re-treatment rates of irradiated sites, symptom control and recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>This will be defined as the time to death measured from the day of randomisation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Palliative Radiotherapy</condition>
  <condition>Radiotherapy, Intensity-Modulated</condition>
  <arm_group>
    <arm_group_label>Standard Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 Gy / 1 Fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Fraction Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8Gy Planning Target Volume / 12Gy Clinical Target Volume +/- 14Gy Gross Tumour Volume / 1 fraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumours</description>
    <arm_group_label>Single Fraction Dose Escalation</arm_group_label>
    <arm_group_label>Standard Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic cancer&#xD;
&#xD;
          -  Recommended for 8Gy/1# palliative radiation&#xD;
&#xD;
          -  Patients with spinal cord compression are eligible for enrolment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling or unable to give informed consent&#xD;
&#xD;
          -  Patients who are recommended multi fraction palliative radiation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Eade</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dylan J Chin</last_name>
    <phone>+612 9463 1337</phone>
    <phone_ext>31337</phone_ext>
    <email>dylan.chin@health.nsw.gov.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carolyn Kwong, RN</last_name>
    <phone>+612 9463 1339</phone>
    <phone_ext>31339</phone_ext>
    <email>Carolyn.Kwong@health.nsw.gov.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Saint Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Kwong, RN</last_name>
      <phone>+61294631339</phone>
      <phone_ext>31339</phone_ext>
      <email>carolyn.kwong@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Heidi Tsang, RN</last_name>
      <phone>+61294631340</phone>
      <phone_ext>31340</phone_ext>
      <email>heidi.tsang@health.nsw.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Eade, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>https://www.varian.com/en-au/products/adaptive-therapy/ethos</url>
    <description>Varian. Varian Adaptive Therapy Ethos.</description>
  </link>
  <reference>
    <citation>Wu JS, Wong R, Johnston M, Bezjak A, Whelan T; Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):594-605. Review.</citation>
    <PMID>12573746</PMID>
  </reference>
  <reference>
    <citation>Rich SE, Chow R, Raman S, Liang Zeng K, Lutz S, Lam H, Silva MF, Chow E. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol. 2018 Mar;126(3):547-557. doi: 10.1016/j.radonc.2018.01.003. Epub 2018 Feb 1. Erratum in: Radiother Oncol. 2019 Jun;135:201.</citation>
    <PMID>29397209</PMID>
  </reference>
  <reference>
    <citation>Caissie A, Zeng L, Nguyen J, Zhang L, Jon F, Dennis K, Holden L, Culleton S, Koo K, Tsao M, Barnes E, Danjoux C, Sahgal A, Simmons C, Chow E. Assessment of health-related quality of life with the European Organization for Research and Treatment of Cancer QLQ-C15-PAL after palliative radiotherapy of bone metastases. Clin Oncol (R Coll Radiol). 2012 Mar;24(2):125-33. doi: 10.1016/j.clon.2011.08.008. Epub 2011 Sep 13.</citation>
    <PMID>21917431</PMID>
  </reference>
  <reference>
    <citation>Sapienza LG, Ning MS, Jhingran A, Lin LL, Leão CR, da Silva BB, Pellizzon ACA, Gomes MJL, Baiocchi G. Short-course palliative radiation therapy leads to excellent bleeding control: A single centre retrospective study. Clin Transl Radiat Oncol. 2018 Nov 22;14:40-46. doi: 10.1016/j.ctro.2018.11.007. eCollection 2019 Jan.</citation>
    <PMID>30555940</PMID>
  </reference>
  <reference>
    <citation>Wu SY, Singer L, Boreta L, Garcia MA, Fogh SE, Braunstein SE. Palliative radiotherapy near the end of life. BMC Palliat Care. 2019 Mar 23;18(1):29. doi: 10.1186/s12904-019-0415-8.</citation>
    <PMID>30904024</PMID>
  </reference>
  <reference>
    <citation>Schuler T, Back M, Hruby G, Carroll S, Jayamanne D, Kneebone A, Stevens M, Lamoury G, Morgia M, Wong S, Grimberg K, Roderick S, Booth J, Eade T. Introducing Computed Tomography Simulation-Free and Electronic Patient-Reported Outcomes-Monitored Palliative Radiation Therapy into Routine Care: Clinical Outcomes and Implementation Experience. Adv Radiat Oncol. 2020 Dec 3;6(2):100632. doi: 10.1016/j.adro.2020.100632. eCollection 2021 Mar-Apr.</citation>
    <PMID>33851063</PMID>
  </reference>
  <reference>
    <citation>Nguyen QN, Chun SG, Chow E, Komaki R, Liao Z, Zacharia R, Szeto BK, Welsh JW, Hahn SM, Fuller CD, Moon BS, Bird JE, Satcher R, Lin PP, Jeter M, O'Reilly MS, Lewis VO. Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA Oncol. 2019 Jun 1;5(6):872-878. doi: 10.1001/jamaoncol.2019.0192.</citation>
    <PMID>31021390</PMID>
  </reference>
  <reference>
    <citation>Ryu S, Deshmukh S, Timmerman RD, Movsas B, Gerszten PC, Yin FF, et al. Radiosurgery Compared To External Beam Radiotherapy for Localized Spine Metastasis: Phase III Results of NRG Oncology/RTOG 0631. International Journal of Radiation Oncology • Biology • Physics. 2019;105(1):S2-S3.</citation>
  </reference>
  <reference>
    <citation>Ong WL, Foroudi F, Milne RL, Millar JL. Variation in the Use of Single- Versus Multifraction Palliative Radiation Therapy for Bone Metastases in Australia. Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):61-66. doi: 10.1016/j.ijrobp.2019.08.061. Epub 2019 Sep 7.</citation>
    <PMID>31505246</PMID>
  </reference>
  <reference>
    <citation>Roos DE, Turner SL, O'Brien PC, Smith JG, Spry NA, Burmeister BH, Hoskin PJ, Ball DL; Trans-Tasman Radiation Oncology Group, TROG 96.05. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother Oncol. 2005 Apr;75(1):54-63. Epub 2004 Oct 28.</citation>
    <PMID>15878101</PMID>
  </reference>
  <reference>
    <citation>Maranzano E, Bellavita R, Rossi R, De Angelis V, Frattegiani A, Bagnoli R, Mignogna M, Beneventi S, Lupattelli M, Ponticelli P, Biti GP, Latini P. Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. J Clin Oncol. 2005 May 20;23(15):3358-65. Epub 2005 Feb 28.</citation>
    <PMID>15738534</PMID>
  </reference>
  <reference>
    <citation>Maranzano E, Trippa F, Casale M, Costantini S, Lupattelli M, Bellavita R, Marafioti L, Pergolizzi S, Santacaterina A, Mignogna M, Silvano G, Fusco V. 8Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial. Radiother Oncol. 2009 Nov;93(2):174-9. doi: 10.1016/j.radonc.2009.05.012. Epub 2009 Jun 10.</citation>
    <PMID>19520448</PMID>
  </reference>
  <reference>
    <citation>Lee KA, Dunne M, Small C, Kelly PJ, McArdle O, O'Sullivan J, Hacking D, Pomeroy M, Armstrong J, Moriarty M, Clayton-Lea A, Parker I, Collins CD, Thirion P. (ICORG 05-03): prospective randomized non-inferiority phase III trial comparing two radiation schedules in malignant spinal cord compression (not proceeding with surgical decompression); the quality of life analysis. Acta Oncol. 2018 Jul;57(7):965-972. doi: 10.1080/0284186X.2018.1433320. Epub 2018 Feb 8.</citation>
    <PMID>29419331</PMID>
  </reference>
  <reference>
    <citation>Job M, Holt T, Bernard A. Reducing radiotherapy waiting times for palliative patients: The role of the Advanced Practice Radiation Therapist. J Med Radiat Sci. 2017 Dec;64(4):274-280. doi: 10.1002/jmrs.243. Epub 2017 Aug 29.</citation>
    <PMID>28851033</PMID>
  </reference>
  <reference>
    <citation>Thavarajah N, Wong K, Zhang L, Bedard G, Wong E, Tsao M, Danjoux C, Barnes E, Sahgal A, Dennis K, Holden L, Lauzon N, Chow E. Continued success in providing timely palliative radiation therapy at the Rapid Response Radiotherapy Program: a review of 2008-2012. Curr Oncol. 2013 Jun;20(3):e206-11. doi: 10.3747/co.20.1342.</citation>
    <PMID>23737690</PMID>
  </reference>
  <reference>
    <citation>Wong S, Roderick S, Atyeo JW, Grimberg K, Porter B, Booth J, et al. Improving the Palliative Patient Journey in Radiation Oncology. International Journal of Radiation Oncology • Biology • Physics. 2019;105(1):S49.</citation>
  </reference>
  <reference>
    <citation>Sandler KA, Mitchell SA, Basch E, Raldow AC, Steinberg ML, Sharif J, Cook RR, Kupelian PA, McCloskey SA. Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology. Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):44-52. doi: 10.1016/j.ijrobp.2018.04.048. Epub 2018 Jun 5.</citation>
    <PMID>30102201</PMID>
  </reference>
  <reference>
    <citation>Brunelli C, Zecca E, Martini C, Campa T, Fagnoni E, Bagnasco M, Lanata L, Caraceni A. Comparison of numerical and verbal rating scales to measure pain exacerbations in patients with chronic cancer pain. Health Qual Life Outcomes. 2010 Apr 22;8:42. doi: 10.1186/1477-7525-8-42.</citation>
    <PMID>20412579</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal North Shore Hospital</investigator_affiliation>
    <investigator_full_name>Professor Thomas Eade</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The results of this trial will be published in a peer reviewed journal. Target journals for publication of this trial include, International Journal of Radiation Oncology Biology Physics</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

